Trials / Terminated
TerminatedNCT04469725
KN046 (a Humanized PD-L1/CTLA4 Bispecific Single Domain Fc Fusion Protein Antibody) in Subjects With Thymic Carcinoma
A Phase 2, Open-Label, Multi-Center Study to Evaluate Efficacy, Safety and Tolerability of KN046 in Subjects With Thymic Carcinoma
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 95 (actual)
- Sponsor
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 2, open-label, multi-center, single arm study in subjects with advanced thymic carcinoma after failure of platinum-based combination chemotherapy. Subjects should have documented progressive disease while on platinum-based combination chemotherapy. If subjects discontinued platinum-based therapy due to reasons other than progressive disease, subjects should have completed at least 2 cycles of platinum-based combination chemotherapy before the commencement of documented progressive disease. Subjects will be treated with KN046 5 milligram per kilogram every 2 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | KN046 | KN046 5 milligram per kilogram, every 2 weeks |
Timeline
- Start date
- 2020-12-02
- Primary completion
- 2023-07-07
- Completion
- 2023-07-07
- First posted
- 2020-07-14
- Last updated
- 2024-03-12
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04469725. Inclusion in this directory is not an endorsement.